Small solid silica nanoparticles (SiNPs) have been used for multivalent carbohydrate presentation in DC-/L-SIGN-mediated viral infection models. Glycosylated SiNPs (glycoSiNPs) were fully characterized by different experimental techniques, including NMR, DLS, TGA, FTIR, and XPS, which confirmed their chemical structures. As a proof-of-concept, the capacity of glycoSiNPs to interact with Concanavalin A (ConA), a model lectin, using DLS binding experiments and UV-vis turbidimetry assays was analyzed. Their antiviral activity was assessed in a cellular assay using an artificial Ebola virus, demonstrating the potent inhibition of DC-SIGN-mediated infection. Notably, glycoSiNPs functionalized with a trivalent Manα1,2Man glycodendron exhibited the strongest inhibitory activity, with an IC of 135 ng/mL and a 170-fold lower efficiency in blocking L-SIGN-mediated viral infection. These findings suggest that glycoSiNPs present a promising approach for developing antiviral agents that selectively target the DC-SIGN pathway over the L-SIGN one.